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Abstract
Background: Familial hypercholesterolemia is a genetic disorder mainly caused by defects in the low-density
lipoprotein receptor gene. Few and limited analyses of familial hypercholesterolemia have been performed in
Malaysia, and the underlying mutations therefore remain largely unknown.
We studied a group of 154 unrelated FH patients from a northern area of Malaysia (Kelantan). The promoter region
and exons 2-15 of the LDLR gene were screened by denaturing high-performance liquid chromatography to
detect short deletions and nucleotide substitutions, and by multiplex ligation-dependent probe amplification to
detect large rearrangements.
Results: A total of 29 gene sequence variants were reported in 117(76.0%) of the studied subjects. Eight different
mutations (1 large rearrangement, 1 short deletion, 5 missense mutations, and 1 splice site mutation), and 21
variants. Eight gene sequence variants were reported for the first time and they were noticed in familial
hypercholesterolemic patients, but not in controls (p.Asp100Asp, p.Asp139His, p.Arg471Gly, c.1705+117 T>G, c.1186
+41T>A, 1705+112C>G, Dup exon 12 and p.Trp666ProfsX45). The incidence of the p.Arg471Gly variant was 11%.
Patients with pathogenic mutations were younger, had significantly higher incidences of cardiovascular disease,
xanthomas, and family history of hyperlipidemia, together with significantly higher total cholesterol and low
density lipoprotein levels than patients with non-pathogenic variants.
Conclusions: Twenty-nine gene sequence variants occurred among FH patients; those with predicted
pathogenicity were associated with higher incidences of cardiovascular diseases, tendon xanthomas, and higher
total and low density lipoprotein levels compared to the rest. These results provide preliminary information on the
mutation spectrum of this gene among patients with FH in Malaysia.
Background
Familial hypercholesterolemia (FH) is caused by defects
in the low-density lipoprotein receptor (LDLR) gene,
which give rise to a well-characterized clinical pheno-
type [1]. The prevalence of heterozygous FH is approxi-
mately 1 in 500 among the general population in most
countries worldwide. The prevalence of homozygotes is
generally about 1 in 1 million [1]. Despite its strong
genetic background, FH shows great variability in phe-
notypic expression in terms of lipid profile, frequency of
xanthomas, and onset and severity of cardiovascular dis-
ease (CVD) [1]. It has been shown that at least 50% of
males and 20% of females with FH who fail to receive
effective treatment suffer from coronary events by the
age of 50 years [2].
The plasma levels of low-density lipoprotein choles-
terol (LDL-C) in FH heterozygotes are lower and more
dependent on other genetic and environmental factors
than those in FH homozygotes. Although the nature of
the molecular defect has some impact on the severity of
hypercholesterolemia, FH heterozygotes with the same
LDLR mutation can have widely different plasma levels
of LDL-C. In all patients with FH caused by LDLR
defects, phenotype severity seems to depend more on
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However the clinical diagnosis is not always evident,
especially in young patients without physical stigmata,
and molecular diagnostic techniques would be helpful in
these cases [4].
The LDLR gene locus is located on chromosome
19p13.1-13.3 and spans 45 kb, with 18 exons and 17
intervening introns, encoding a mature protein of 839
amino acids. Mutations can occur in the promoter, or in
the introns or exons. The majority of variants fall within
the ligand-binding (40%) or epidermal growth factor
precursor-like (47%) domains, with the highest fre-
quency of mutations reported in exon 4 (20%) [5]. This
high frequency can be explained by a selection bias; i.e.,
individuals with functional mutations in this region may
be overrepresented in the lipid clinic populations sur-
veyed for FH screening [6]. However, when the number
of mutations is normalized to base pairs, the mutation
rate is similar in most exons, except for the promoter
region and exons 16-18 [5].
A total of 1,066 individual validated LDLR variants
from FH patients are now listed on the University Col-
lege London (UCL) database [5]. The LDLR FH data-
base http://www.ucl.ac.uk/ldl underlines the vast
molecular heterogeneity of this disorder [5]. The current
study therefore aimed to describe the molecular spec-
trum of FH in Malaysian subjects (by screening the
most likely affected exons), and to identify and correlate
the LDLR gene mutations with the clinical manifesta-
tions of FH.
Results
One hundred and fifty-four patients were recruited. Their
clinical characteristics and lipid profiles are presented in
Table 1. Of these, 52.6% were females and 47.4% were
males, with a mean age of 44.6 years. A high prevalence
of cardiovascular disease (CVD) was reported (68.2%),
with the mean age of presentation at 41.5 years. Around
twenty-three percent of patients were current smokers.
A family history of premature CVD (PCVD) was reported
in 57.8%, and 58.4% had a family history of hyperlipide-
mia. Tendon xanthoma (TX) was present in 40.9%, and
xanthelasma occurred in 25.3%. The mean levels of total
cholesterol (TC) and LDL-C were 7.9 mmol/l and
5.0 mmol/l, respectively, while the TC: high-density lipo-
protein (HDL) ratio without lipid-lowering therapy was
6.6. Eighty control subjects were recruited with a mean
age of 39.3 years, a mean TC level of 5.0 mmol/l, and a
mean LDL-C level of 2.9 mmol/l.
LDLR gene variants were identified by analyzing the
promoter region of the LDLR gene and the exon-intron
boundaries of exons 2-15 using denaturing high-
performance liquid chromatography (DHPLC), and het-
eroduplex peaks were sequenced. Table 2 shows the
different sequence variants that were identified in 154
unrelated FH patients attending the Cardiology Clinic in
the Hospital Universiti Sains Malaysia (HUSM), Kelantan,
Malaysia.
Screening of all clinically diagnosed cases with FH
identified 29 LDLR variants in 117 of 154 subjects
included in the study (76.0%). Six of the variants were
detected in the control group, with a non-significant dif-
ference in frequency between FH subjects and controls
(c.190+58C>T, c.1060+7 T>C, c.1060+10 G>C, p.
Pro539Pro, c.1705+56C>T and p.Arg744Arg). All of the
Table 1 Demographics, Clinical findings and Biochemical
Data among FH patients
Variables (n = 164)
A) Demographic characteristics
Age (year) * 44.6(12.0)
Sex n (%)
Female 81(52.6)
Male 73(47.4)
Ethnicity n (%)
Malays 152(98.7)
Non-Malays 2(1.3)
Smoking n (%)
Current 36(23.4)
Ex-smokers 21(13.6)
Non-smokers 97(63.0)
Alcohol consumption n (%) 1(0.6)
B)Medical history
CVD n (%) 105(68.2)
Age of onset of CVD(years)* 41.5(7.6)
Hypertension n (%) 34(22.1)
Stroke n (%) 4(2.6)
On LLT n (%) 126(81.2)
Family history of PCVD n (%) 89(57.8)
Family history of hyperlipidemia n (%) 90(58.4)
Family history of tendon xanthoma n(%) 48(31.2)
C) Medical examination
SBP (mmHg) * 127.1(15.9)
DBP (mmHg)* 77.7(10.9)
BMI (kg/m2)* 27.4(4.8)
Tendon xanthomas n(%) 63(40.9)
Arcus n (%) 77(50.0)
Xanthelasma n (%) 39(25.3)
D) Lipid profile parameters
TC(mmol/l)* 7.9(1.0)
TG (mmol/l)* 1.9(0.8)
HDL-C (mmol/l)* 1.3(0.3)
LDL-C (mmol/l)* 5.0 (0.9)
TC/HDL-C ratio * 6.6(2.3)
*The data are expressed as mean (S.D).
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Variant name* Location In Silico analysis Statistical analysis Miscellaneous Reference
Non-
pathogenic
Pathogenic Patient
n(%)
a
Control
n(%)
b
** P
value
Nil promoter
c.81C>T;p.Cys27Cys exon 2 √ 1(0.6) rs2228671 NCBI; UCL***
c.190+56G>A Intron 2 √ 3(1.9) rs3745677 NCBI; UCL***
c.190+58C>T intron 2 √ 7 (4.5) 4(5) 0.9 rs3745678 NCBI
c.300C>T;p.Asp100Asp exon 3 √ 1(0.6) Synonymous Unlikely to cause
pathogenicity
No
reference
c.910G>A;p.Asp304Asn exon 6 √ 7(4.5) Changes in amino acid Benign by
Poly Phen
UCL***
c.940+36G>A intron 6 √ 3(1.8) rs13306513 NCBI
c.1060+7T>C intron 7 √ 18
(11.7)
8(10) 0.7 rs2738442 NCBI
c.1060+10G>C intron 7 √ 5(3.2) 3(3.8) 0.9 rs12710260 NCBI;
HGMD****
c.1186+41T>A intron 8 √ 1(0.6) Location is unlikely to cause
pathogenicity
No
reference
c.1194C>T;p.Ile398Ile exon 9 √ 5(3.2) rs13306498 NCBI
c.1359-30C>T intron 9 √ 2(1.3) rs1003723 NCBI
c.1411A>G;p.Arg471Gly exon 10 √ 17
(11.0)
Changes in amino acid Benign by
Poly Phen
No
reference
c.1617C>T;p.Pro539Pro exon 11 √ 6 (3.9) 4(5) 0.7 rs5929 NCBI
c.1705+56C>T intron 11 √ 12 (7.8) 2 (2.5) 0.08 rs4508523 NCBI
c.1705+112C>G intron 11 √ 1(0.6) Location is unlikely to cause
pathogenicity
No
reference
c.1706-55A>C intron 11 √ 6 (3.9) rs2738447 NCBI
c.1706-69G>T intron 11 √ 1(0.6) rs7259278 NCBI
c.1705+117T>G intron 11 √ 2(1.3) Location is unlikely to cause
pathogenicity
No
reference
c.1773C>T;p.Asn591Asn exon 12 √ 7(4.5) rs688 NCBI
c.1959T>C;p.Val653Val exon 13 √ 1(0.6) rs5925 NCBI
c.2232A>G;p.Arg744Arg exon 15 √ 5 (3.2) 3(3.8) 0.8 rs5927 NCBI
c.190+4A>T intron 2 √ 1(0.6) Possibly pathogenic UCL**
c.301G>A;p.Glu101Lys exon 3 √ 11(7.1) Possibly pathogenic UniProt;
UCL***
c.415G>C;p.Asp139His exon 4 √ 1(0.6) Probably pathogenic No
reference
c.601G>A;p.Glu201Lys exon 4 √ 9(5.8) Probably pathogenic UCL**
c.763T>A;p.Cys255Ser exon 5 √ 10(6.5) Probably pathogenic UCL***
c.1706_1845dup;p.
Asp616IlefsX96
exon 12 √ 2(1.3) Pathogenic No
reference
c.2100C>G;p.Asp700Glu exon 14 √ 5(3.2) Possibly pathogenic UniProt;
UCL***
c.1996_2012del17;p.
Trp666ProfsX45
exon 14 √ 4(2.6) Pathogenic No
reference
*Naming of the variants done according to Nomenclature of the Human Genome Variation Society (HGVS).
** Chi square test.
*** http://www.ucl.ac.uk/Library/database.
****Human Genome Mutation Database.
*****Nonsense-mediated decay.
rs reference sequence from NCBI.
a percentage from 154.
b percentage from 80**.
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except for c.2232A>G; (p.Arg744Arg) in exon 15 and
c.1060+7 T>C in intron 7, which were homozygous.
The most frequent variant was the c.1060+7 T>C,
with a frequency of 11.7% (18/154), followed by the
c.1411A>G substitution in exon 10, resulting in p.
Arg471Gly variant, which was detected at a frequency of
11.0% (17/154).
Eight variants were previously unreported while the
other 21 variants have been previously described in pub-
lic databases http://www.hgmd.cf.ac.uk; http://www.ucl.
ac.uk/ldlr, and http://www.ncbi.nlm.nih.gov/Genbank
(Table 2).
There was considerable diversity in the types of var-
iants, as eight LDLR gene mutations were reported (1
frameshift, 1 large rearrangement, 5 missense and 1
splice site).
One novel frameshift mutation was reported, p.
Trp666ProfsX45 (Figure 1), resulting from the deletion
of 17 nucleotides (c.1996_2012del 17). A novel silent
variant was reported in one FH subject (p.Asp100Asp).
Two novel missense variants were also reported,
p.Asp139His and p.Arg471Gly.
A duplication of exon 12 was found to co-segregate
with hypercholesterolemia in two family members.
A typical result of duplication is shown in the electro-
phoregram in Figure 2A and 2B, which shows the peak
height for each of the test and control probes. The 37
labeled peaks included probes for the LDLR gene pro-
moter, its 18 exons, 16 reference probes, and 2 probes
for the upstream and downstream genes in chromosome
19. The peak height that represents the exon 12 probe
was at 8,084 relative fluorescence units (RFU), which
was about 1.7 times that of the control sample (4,768
RFU), suggesting duplication. This result was confirmed
by second multiplex ligation-dependent probe amplifica-
tion (MLPA).
The c.190+4A>T splice site mutation was reported in
one FH subject.
Three previously reported silent variants, p.Ile398 Ile,
p.Asn591Asn, and p.Val653Val, were found in the FH
subjects but not in the control group, while one silent
variant (p.Pro539Pro) was reported in both cases and
controls. One novel variant in intron 8 (c.1186+41T>A)
and two previously unreported variants in intron
11 (c.1705+117T>G and c.1705+112C>G) were also
noticed.
In silico analyses of variant effects
We categorized 21 variants as non-pathogenic (Table 2).
Alamut™identified fifteen of them as “might be poly-
morphism” with their designated SNP ID from the
NCBI. Another software, Polymorphism phenotyping
(PolyPhen), predicted two other exonic variants
(c.910G>A;p.Asp304Asn and c.1411A>G;p.Arg471Gly)
to be “benign”, and these were therefore also regarded
as non-pathogenic. We also categorized a synonymous
variant, c.300C>T;p.Asp100Asp, as non-pathogenic
because no evidence of splicing aberrations or changes
in protein structure from the in-silico analyses although
it may stall translation by requiring the use of low abun-
d a n c et R N A s .W ew e r eu n a b l et op r e d i c tt h e
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Figure 1 Sequencing analysis demonstrated the detection of Trp666ProfsX45 mutation in exon14. A) Nucleotide sequences are shown
by chromatogram before deletion (red square shows the deleted region, B) Nucleotide sequences are shown by chromatogram after deletion C)
Nucleotide sequences are shown by alignment with normal exon 14 deletion at 30923-30939.
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c.1705+117T>G, c.1705+112C>G). However, due to
their positions, they seem unlikely to cause pathogeni-
city and therefore were categorized as non-pathogenic.
Eight variants were categorized as pathogenic, in
which the detailed in-silico analyses are provided in
Table 3. Of these, two (c.1706_1845dup;p.Asp616I-
lefsX96 and c.1996_2012del;p.Trp666ProfsX45) were
categorized as pathogenic based on their frameshift
effects. Two others (c.301G>A; p.Glu101Lys and
c.2100C>G;p.Asp700Glu) were categorized as ‘’possibly
pathogenic’’ based on Uni-Prot reports. Another one
(c.190+4A>T) was categorized as possibly pathogenic
based on further analyses using Analyzer Splice Tool
(AST) and NNSPLICE softwares. According to Saphiro
and Senapathy (1987) [7], it occurred within a con-
served 5’splice-donor site. However, its true effects
have yet to be clarified with an mRNA analysis. Three
exonic mutations (c.601G>A; p.Glu201Lys, c.763T>A;p.
Cys255Ser and c.415G>C;p.Asp139His) were predicted
by Poly Phen software as “probably damaging” and
were therefore regarded as pathogenic mutations
(Table 3).
Six previously unreported variants were submitted to
GenBank and assigned accession numbers (Table 4).
Phenotypes of FH subjects with identified LDLR gene
variants
In order to evaluate the relevance of LDLR pathogenic
mutations to the clinical presentation of the disease,
individuals were classified into two groups according to
the pathogenicity of the gene defect: those with non-
pathogenic variants (n = 112) were compared to those
with pathogenic mutations (n = 42) (Table 5). Patients
with pathogenic mutations were younger (P = 0.007),
have a higher frequency of CVD (P = 0.001) with
younger age of presentation (P = 0.03), higher frequency
of family history of hyperlipidemia (P = 0.03), xantho-
mas (P < 0.001), and higher levels of TC (P = 0.001)
and LDL-C (P = 0.02).
 
 


Figure 2 A- The multiplex ligation-dependent probe amplification kit of control subject. The red arrow shows peak height of exon 12
probe of 4768 RFU. B-A case of a duplication of exon 12 probe. The red arrow shows the peak height of 8084 RFU. The data were analyzed
using the Peak Scanner software.
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Molecular genetic diagnosis is currently the most specific
method for identifying patients with FH. Although numer-
ous LDLR gene mutations have been identified in FH
patients, genetic data for the Malaysian population are
rare [4,8]. The present study cohort of 154 patients with
clinical features of FH was relatively young (with a mean
age of 44.6 years), and already had a high prevalence of
CVD (68.2%). The average LDL-C level was classified as
high, according to National Cholesterol Education Pro-
gram (NCEP ATP III) classification [9]. This, together
with the high prevalence of CVD, were consistent with the
recognized association of elevated LDL-C levels with a
high risk of atherosclerotic disease [10].
Table 3 The predicted pathogenic variants
Name of
Variant
Location Analysis by NNSPLICE Analysis by
AST
Alamut Uni prot report Poly Phen
c.190+4A>T Intron 2 Before mutation the score
was 0.54. After mutation,
not recognized as splice
site
Before change
the score was
70.3 and ΔG
-3.6
After mutation
the score was
60.32 and ΔG
-3.0
c.301G>A;p.
Glu101Lys
Exon 3 Possibly
pathogenic
as reported
by UniProt
(FTId:
VAR_005315)
Change from medium size and acidic (E) to
large size and basic (K)
c.415G>C;p.
Asp139His
Exon 4 Changes
in amino
acid.
Disruption
of ligand
binding
site
c.601G>A;p.
Glu201Lys
Exon 4 Changes
in amino
acid.
Disruption
of ligand
binding
site
c.763T>A;p.
Cys255Ser
Exon 5 Changes
in amino
acid.
Disruption
of ligand
binding
site
c.1706_1845dup;
p.Asp616IlefsX96
Exon 12 Pathogenic This duplication creates a frame shift starting
at codon Asp616. The new reading frame
ends in a STOP codon 95 positions
downstream.
The mRNA produced might be targeted for
nonsense mediated decay (NMD).
c.1996_2012del;
p.
Trp666ProfsX45
Exon 14 Pathogenic This deletion creates a frame shift starting at
codon Trp666. The new reading frame ends
in a STOP codon 44 positions downstream.
The mRNA produced might be targeted for
nonsense mediated decay (NMD).
c.2100C>G;p.
Asp700Glu
Exon 14 Possibly
pathogenic
as reported
by UniProt
(FTId:
VAR_005412)
Change in 3 D structure of protein
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ter region and in exons 2-15 of the LDLR gene was
investigated, and LDLR variants were identified in 117
out of 154 patients (76.0%). These comprised 8 pre-
viously unreported and 21 previously reported LDLR
sequence variations. Eight pathogenic mutations were
reported, including one intronic (c.190+4A>T).
One subset was relatively common, such as a variant
in exon 10 (p.Arg471Gly), which was found in 17
patients. The donor splice site mutation (c.190+4A>T)
was the commonest among Filipino FH [11], while
L547V mutation was predominant among Japanese FH
[12]. The frequent detection of a deleterious mutation
may be the result of consanguinity, recurrent mutational
events, genetic drift, or multiple introduction of the
mutation into a population [13].
The overall mutation rate of 42.2% (65/154), which was
higher than that reported in previous studies of Malaysian
FH (26%) [4] or Filipino FH (20%) patients [11], but lower
than that reported in European populations (52%) [14].
Only the p.Cys255Ser, p.Asn591Asn, and p.Val653Val
variants detected in the current study have previously
been reported among Malaysian FH subjects [8]; the
remainders were newly identified in this study popula-
tion. This may be attributed to the high sensitivity of
DHPLC for detecting gene sequence variants, and the
restricted inclusion criteria.
Five missense mutations that resulted in altered
amino acids (p.GluA101Lys, p.Asp139His, p.Glu201Lys,
p.Cys255Ser and p.Asp700Glu) were predicted to exert
pathogenic effects based on the in silico analyses.
p.Glu101Lys was predicted to be pathogenic by Ala-
mut™software with change from medium size and
acidic (Glutamate) to large size and basic (Lysine). This
residue occurs in the second disulfide-rich repeat in the
binding domain of the receptor protein, and affects pro-
cessing and intracellular transport of the newly synthe-
sized protein. It was suggested that the normal
formation of disulfide bonds in the second repeat may
be impeded in the mutant protein [15].
p.Asp700Glu was predicted to be pathogenic by Ala-
mut™software with change in the 3 D structure of the
protein. It was reported among Spanish FH subjects
[16].
p.Asp139His is a missense mutation, reported for the
first time in this study, located in the ligand binding
domain and was predicted to be ‘’probably damaging’’
by PolyPhen due defect in the ligand binding site.
p.Glu201Lys and p.Cys255Ser are previously reported
mutations among Russian patients [17] and Malaysian
patients [8], respectively and were predicted to be
‘’probably damaging’’ by PolyPhen.
I th a sb e e nr e p o r t e dt h a tas i g n i f i c a n tp r o p o r t i o n
(approximately 18.9%) of theg e n es e q u e n c ev a r i a n t s
Table 4 Novel variants of LDLR gene that were submitted
to genbank and their accession numbers
Variant name Accession no.
p.Asp100Asp HM853677
p.Asp139His HM853677
p.Arg471Gly HQ190922
c.1705+117 T>G HQ190924
c.1186+41T>A HQ190917
p.Trp666ProfsX45 HM369522
Table 5 Association of LDLR sequence variants among
patients to their demographic characteristics, medical
history, clinical finding and lipid profile parameters
(n = 154)
Variables (n = 164) Patients with
non-
pathogenic
variants
(n = 112)
(72.7%)
Patients with
pathogenic
variants
(n = 42)
(27.3%)
P
value
A)Demographic
characteristics
Age (year)*
a 46.2(11.4) 40.3(12.7) 0.007
Sex 60(53.6) 21(50.0) 0.72
Female 52(46.4) 21(50.0)
Male
B) Medical history
CVD (%)
b 68(60.7) 37(88.1) 0.001
Age of onset of CVD(%)
b ** 42.7(6.4) 39.3(9.3) 0.03
Hypertension (%)
b 30(26.8) 4(9.5) 0.03
Family history of PCVD (%)
b 60(53.6) 29(69.0) 0.1
Family history of
hyperlipidemia (%)
b
59(52.7) 31(73.8) 0.03
Family history of tendon
xanthoma (%)
b
32(28.6) 16(38.1) 0.3
C) Clinical examination
BMI 27.1(4.5) 28.2(5.5) 0.25
Tendon xanthoma 35(31.3) 28(66.7) <0.001
(%)
bArcus 57(50.9) 20(47.6) 0.9
(%)
bXanthelasma (%)
b 24(21.4) 15(35.7) 0.09
D) Lipid profile
parameters
a
TC(mmol/l)* 7.7(0.9) 8.3 (1.2) 0.001
TG (mmol/l)* 1.9(0.8) 1.7(0.9) 0.19
HDL-C (mmol/l)* 1.3(0.3) 1.3(0.4) 0.96
LDL-C (mmol/l)* 4.9(0.8) 5.2(1.1) 0.02
TC/HDL-C ratio * 6.5(2.4) 6.9(1.9) 0.23
*Data are expressed as mean (S.D).
a ANOVA test was used.
b Chi square test was used.
c The pathogenic mutations are reported 43 times according to Table 2 and
these were found among 42 patients as one patient was reported to have 2
pathogenic mutations [Glu101Lys+Dup exon 12].
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coding sequence [18]. These variations are often located in
the 5’ splice-donor site or the 3’ splice-acceptor site of an
intron, and are predicted to result in either exon skipping
or retention of an intron in the mRNA, although this has
not always been confirmed experimentally. One such var-
iant, c.190+4A>T, has been reported in this study as well
as in the Netherlands [19] and the Philippines [11]. We
reported the possibility that it may cause splicing abnorm-
alities through an in-silico analysis. However, the true
effect should be experimentally clarified using splicing
analysis.
For c.1060+10G>C variant in intron 7, it was reported
in French and Greek FH patients [20,21]. In the present
study this variant was reported among FH subjects and
control groups with a non significant difference in the
occurrence between both groups which may indicate
that this variant may be a polymorphism.
c.1359-30C>T is detected in unrelated FH individuals
in Denmark [22]. Webb et al. [23] failed to detect any
effect of this polymorphism on plasma lipid concentra-
tions in their population. p.Ile398 Ile, p.Pro539Pro, and p.
Cys27Cys are previously reported among European [24],
Russian [25] and Chinese FH patients [26], respectively,
with unknown clinical associations with the disease.
p.Trp666ProfsX45 was identified in four unrelated
patients within this study, which could be attributed to
a founder effect. The extent or nature of the deletion in
the DNA was not clear, and the amplified mutant frag-
ment was therefore cloned and sequenced. The pre-
dicted translation products of the alleles carrying this
mutation resulted in the creation of premature stop
codon downstream of the deletion.
We identified a large genomic rearrangement
(c.1706_1845dup;p.Asp616IlefsX96), a duplication of exon
12, in the LDLR gene which have not previously been
detected among Malaysian FH patients [8,27]. It is inter-
esting to note that while large deletion generally repre-
sents 85% of large rearrangements in the LDLR gene [5],
our finding showed the predominance of a large duplica-
tion and the absence of large deletions. Large duplica-
tions seem to be much more prevalent than large
deletions among the Malaysian population, while large
deletions are more common than large duplications in
North European Caucasians [28]. Therefore, the preva-
lence of large duplications/rearrangements in FH patients
indicates that MLPA should be included in the diagnostic
service for dominant hypercholesterolemia.
The duplicated exon 12 (c. c.1706_1845dup; p.
Asp616IlefsX96) is predicted to cause a frameshift pro-
tein, with premature termination 95 positions down-
stream. Due to its nucleotide number (1706-1845 bp)
that were duplicated, either deletion or duplication of
exon 12 will cause frameshifted protein, (i.e. disruption
of reading frame starting from the point of deletion or
duplication). The mutation effect is different with that
of previously reported deletion of exon 15 [29] which is
a common yet mild cause of FH in Finland. Deletion of
exon 15 caused only internal truncation of the protein
without inducing premature termination, since the read-
ing frame was maintained.
In silico predictions of the eight variants categorized
as pathogenic may provide grounds for further experi-
mental studies aimed at revealing mRNA abnormalities,
as well as altered protein-protein interactions and loss
of function.
mRNA expression studies could be performed for the
c.1706_1845dup; p.Asp616IlefsX96 and c.1996_2012del;
p.Trp666ProfsX45, as they were also predicted to be tar-
gets for nonsense-mediated decay.
There were significant differences in baseline LDL-C
levels between the two patients groups; subjects with
pathogenic mutations had a mean baseline LDL-C level
of 5.2 mmol/l, compared with level of 4.9 mmol/l in
patients of the non pathogenic group.
A l s ot h o s ew i t hp a t h o g e n i cm u t a t i o n ss h o wam o r e
severe phenotype (higher frequencies of CVD, TX, and
family history of hyperlipidemia) than those with non
pathogenic variants which may increase the likelihood of
their pathogenicity. The exact decision about the func-
tional implications should be done by in vitro functional
study.
The presentation of TX as a diagnostic sign of FH was
interesting in the current study population, as only
40.9% of FH subjects showed TX. This emphasizes the
importance of DNA analysis, because no definite diag-
nosis of FH can be made without the identification of
TX or a defined mutation.
Regarding those patients who showed definite clinical
manifestations of FH but no identified LDLR sequence
variations, the following possibilities exist: (1) they may
have defects that are linked to the LDLR gene variant
within deep intronic regions, affecting expression or
splicing of the gene; (2) they may have exon defects that
have not been screened; (3) the defect may lie in
another gene involved in LDL-C metabolism, such as
the apolipoprotein gene or the proprotein convertase
subtilisin/kexin type 9 (PCSK 9) gene; or (4) it is possi-
ble that polygenic factors interacting with environmental
factors may lead to a clinical diagnosis mimicking the
FH phenotype [30]. It is also likely that some patients
with no identified mutation do not have true monogenic
autosomal dominant hypercholesterolemia. The clinical
diagnostic criteria for FH are not precise, and no family
studies have been carried out in patients with any
detected mutations to clarify this.
There were several limitations of the present study.
FH patients are generally seen by cardiologists when
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etiology is not always investigated. This could explain
the low number of FH patients recruited in the study
sample. This cohort was therefore representative of FH
patients who are referred to specialists because of a
severe lipid phenotype, but not of those who remain
undiagnosed, who may have milder phenotypes [31].
The DHPLC method used here has been reported to
show a sensitivity of 96% [32], and an additional 4% of
LDLR mutations may thus have remained undetected.
Furthermore, several exons with a reportedly low muta-
tion detection rate were not examined; the detection
rate may have been increased by a further 3-4% (repre-
senting the percentage of mutations in exon 1, 16,17
and 18 [5] if all exons had been included. Additionally,
only 30-50 base pairs of the LDLR introns were exam-
ined by the primers used here, and mutations may exist
in other regions, although few have been reported [5].
Conclusion
In summary, 29 LDLR gene sequence variants were
detected in 76% of the analyzed patients with a clinical
diagnosis of FH. Most of these variants were reported
for the first time among Malaysians, with eight variants
discovered in this report. Patients with pathogenic
mutations had a higher rate of CVD and higher TC and
LDL-C levels than those with non-pathogenic variants.
These findings support the usefulness of genetic testing
in FH, beyond its ability to provide an unequivocal diag-
nosis of the condition.
Methods
The target population included dyslipidemic patients
attending the Cardiology Clinic in HUSM. One hundred
and fifty-four subjects gave written, informed consent to
participate in this study. The included subjects were
patients who fulfilled the Simon Broome Familial
Hypercholesterolemia Register diagnostic criteria for FH
[2]. Patients with suspected causes of secondary hyperli-
pidemia were excluded from the study [33]. Demo-
graphic data, medical history, lipid-lowering therapy,
physical examination for detection of the presence of
TXs, xanthelasma, and arcus cornealis were recorded.
Pre-treatment lipid profiles were obtained from the
patients’ records and family history of PCVD was
obtained from all patients using a standardized form.
Eighty control subjects were recruited to detect the
presence of nucleotide substitutions that could be
regarded as single nucleotide polymorphisms. The con-
trol subjects were randomly chosen healthy volunteers
from the staff of Universiti Sains Malaysia, who had no
previous history or family history of hyperlipidemia or
PCVD, no history of secondary causes of hyperlipidemia
and no any clinical signs of hyperlipidemia. Ethical
approval for the study was obtained from Universiti
Sains Malaysia’s Research and Ethics Committee.
Molecular analysis
Peripheral venous blood (2 ml) was collected from
patients and controls into tubes containing potassium
ethylenediaminetetraacetic acid, and genomic DNA was
extracted by (Qiagen, Hilden, Germany) kit. The sam-
ples were then stored at -20°C until further analysis.
A further 3 ml was collected and analyzed to exclude
secondary causes of hyperlipidemia.
All patient and control subjects were screened for
mutations within the LDLR gene. Thirteen pairs of pri-
mers based on the LDLR reference sequence obtained
from the GenBank database (accession no. NT_011295)
were designed to cover the regions previously shown to
contain the highest prevalence of mutations [5] (promo-
ter region and exons 2-15), including 30-50 bp regions
of the introns covering the exon-intron junctions to
detect potential splice site mutations. Briefly, samples
were analyzed by polymerase chain reaction (PCR) stan-
dardized using genomic DNA and primer pairs to
amplify the target exons. PCR was performed in 20 μl
reactions. Each reaction contained 0.5 μM of each for-
ward and reverse primer, 0.16 mM dNTPs, 2.5 mM
MgCl2, 1 × PCR buffer, 0.75 U Taq DNA polymerase
and diluted DNA template (~50 ng). Details of the pri-
mer sequences, annealing temperatures, and expected
PCR products are available in Additional file 1. Before
DHPLC analysis, 5 μl of the PCR reaction mixture was
run on a 2% agarose gel with a 100-bp marker for
comparison.
DHPLC and direct sequencing
All patients and controls were screened for point muta-
tions using DHPLC. Mutation analysis was performed
using a partially inert Helix System (Varian, Inc, USA).
The melting temperatures of the DNA fragments were
predicted using the procedure discussed at http://inser-
tion.stanford.edu./melt.html. The PCR products were
d e n a t u r e da t9 5 ° Cf o r5m i na n dc o o l e dt o6 5 ° Ca ta
rate of 1°C/min. After slow re-annealing, the sample was
injected directly at the optimum temperature identified
by mapping, and the elution profile of the samples was
compared to the elution profile of the control. The sin-
gle peak pattern of the sample under partial denatura-
tion conditions indicated the absence of mismatch, and
thus identified mutations. In contrast, samples that
demonstrated different peak patterns were considered to
be heteroduplex gene variants, and bidirectional sequen-
cing of purified PCR products from these cases was per-
formed to confirm the results of DHPLC. PCR
fragments were sequenced using the ABI PRISM BigDye
terminator cycle model ABI Prism 3100 Genetic
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ing to the manufacturer’s recommendations.
Multiplex Ligation Dependent Probe Amplification (MLPA)
To detect large rearrangements within the coding sequence
of the LDLR gene, samples were analyzed using MLPA, in
accordance with the manufacturer’s protocol (Kit P062,
MRC-Holland, Amsterdam, The Netherlands). At least five
control samples were analyzed simultaneously. The PCR
products were fractionated on an ABI sequencer. The data
were retrieved using Peak Scanner software (v1.0), and
exported to a Microsoft Excel spreadsheet for further ana-
lysis of peak heights. The peak heights of non-ligated
probes were negligible compared with those of the probe
fragments. The presence of a sequence variant was con-
firmed by a second MLPA analysis. The expected normal-
ized values were 1.0, 0.5, and 1.5 for normal, heterozygous
deletion, or duplication, respectively [34].
In silico analyses of variant effects
Online computer programs were used to analyze the
effects of the nucleotide substitutions. All the variants
were subjected to in silico analyses using Alamut™v1.54
(Interactive Biosoftware, Rouen, France) [35], which
screened for splicing abnormalities as well as protein
changes. Variants without identifiable pathogenicity
were further categorized into those located within splice
sites [7] and those located within exons and beyond
splice sites. Variants located within splice sites were
further analyzed using the online software NNSPLICE
v0.9 [36]http://www.fruitfly.org/seq_tools/splice.html,
with a cutoff value of 0.4, and AST [7,37,38]http://ibis.
tau.ac.il/ssat/Splice SiteFrame.htm, to predict changes in
the splice sites. Variants located within exons in which
Alamut™could not predict the pathogenicity were sub-
jected to analysis with Poly Phen [39], which is an auto-
matic tool for predicting the possible impact of an
amino acid substitution on the structure and function of
a human protein. It classifies amino acid substitutions as
probably damaging, possibly damaging, or benign, and
provides position-specific independent count scores for
wild-type and variant proteins mapped to a known 3 D
structure http://genetics.bwh.harvard.edu/pph/[39].
Nucleotide numbers were designated using the LDLR
sequence reported at http://www.ucl.ac.uk/fh, with
cDNA numbering beginning with A of ATG = 1. The
mutations were designated following the system of the
Human Genome Variation Society http://www.hgvf.org.
Mutation was defined as sequence change which is
clearly designated as FH causing, such as frameshifts
and those predicted to be pathogenic by computer pro-
grammes. The rest of the variants were simply called as
variants.
Statistical analysis
The distributions of quantitative variables were tested
for normality. An initial descriptive analysis was carried
out using number of cases and percentages for qualita-
tive variables and mean (SD) for quantitative variables
with a normal distribution. Quantitative variables were
compared using independent t-test, and qualitative vari-
ables were analyzed using chi-squared tests. Genotype
frequencies were also compared using chi-squared tests.
A global significance level of P < 0.05 was used for all
analyses. All statistical analyses were performed with
SPSS software (v13.0, SPSS, Inc., Chicago, Illinois). Pre-
treatment levels of TC, HDL-C, triglycerides, and LDL-
C and TC/HDL-C ratio were used for statistical analysis.
Additional material
Additional file 1: Supplementary on line materials.
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